Line 71: | Line 71: | ||
{{#tag:html| | {{#tag:html| | ||
<h1>Results</h1> | <h1>Results</h1> | ||
− | In a first step, we wanted to validate our AP. Therefore, we added theophylline with a concentration of 100 µM to our inoculated culture and performed two rounds of PREDCEL. Afterwards, we determined the phage titers by plaque assays. Our theophylline treated culture displayed approximately two times higher phage titers than the non-treated control culture . | + | In a first step, we wanted to validate our AP. Therefore, we added theophylline with a concentration of 100 µM to our inoculated culture and performed two rounds of PREDCEL. Afterwards, we determined the phage titers by plaque assays. Our theophylline treated culture displayed approximately two times higher phage titers than the non-treated control culture. |
Using the same experimental conditions, but replacing the theophylline treatment by a 300 µM caffeine treatment, we verified the functionality of CYP1A2 and thus of our SP. If caffeine is added to the culture CYP1A2 catalyzes the reaction from caffeine to theophylline. The resulting increase of the theophylline concentration further activates the riboswitch on the AP and phage propagation is stimulated (Fig.6). | Using the same experimental conditions, but replacing the theophylline treatment by a 300 µM caffeine treatment, we verified the functionality of CYP1A2 and thus of our SP. If caffeine is added to the culture CYP1A2 catalyzes the reaction from caffeine to theophylline. The resulting increase of the theophylline concentration further activates the riboswitch on the AP and phage propagation is stimulated (Fig.6). | ||
For the evolution of proteins via PREDCEL the addition of a Mutagenesis Plasmid (MP) is essential. For our cytochrome engineering approach we have chosen MP4, which induces a medium mutation rate (REFERENZ!!). After six iterations of our optimized PREDCEL workflow, we performed plaque assays and sequenced single plaques. The sequenced plaques showed five recurrent mutations demonstrating that we are able to induce mutations with our experimental setup and that we are able to evolve enzymes (Fig.7). | For the evolution of proteins via PREDCEL the addition of a Mutagenesis Plasmid (MP) is essential. For our cytochrome engineering approach we have chosen MP4, which induces a medium mutation rate (REFERENZ!!). After six iterations of our optimized PREDCEL workflow, we performed plaque assays and sequenced single plaques. The sequenced plaques showed five recurrent mutations demonstrating that we are able to induce mutations with our experimental setup and that we are able to evolve enzymes (Fig.7). | ||
Line 79: | Line 79: | ||
Figure 6: Results of Riboswitch and CYP1A2 testing in PREDCEL| | Figure 6: Results of Riboswitch and CYP1A2 testing in PREDCEL| | ||
Plaque assays after two passages of CYP1A2 PREDCEL demonstrating the functionality of the Accessory Plasmid and the Selection Plasmid, respectively. | Plaque assays after two passages of CYP1A2 PREDCEL demonstrating the functionality of the Accessory Plasmid and the Selection Plasmid, respectively. | ||
+ | }} | ||
+ | {{Heidelberg/templateus/Imagesection|https://2017.igem.org/File:T--Heidelberg--Team_Heidelberg_2017_Mutationen_PREDCEL_MP.png| | ||
+ | Figure 7: Mutations in CYP1A2 gene by PREDCEL after 2 passages| | ||
+ | Sequencing result illustrating the new point mutations of the CYP1A2 gene. Recurrent mutations are indicated in red. | ||
}} | }} | ||
{{Heidelberg/templateus/Contentsection| | {{Heidelberg/templateus/Contentsection| |
Revision as of 22:59, 1 November 2017
Cytochrome Engineering
Directing CYP1A2 product specificity
Introduction
Enzymes, i.e. proteins mediating specific, catalytic functions, are amongst the most powerful molecular machines invented by nature. Since decades, humans utilize naturally occurring enzymes as bio detergents (e.g. in washing powderThe engineering of novel enzymes catalyzing reactions that do not or only inefficiently occur in nature holds great promise for biotechnological production of regenerative fuel, biomaterials and novel pharmaceuticals, e.g. based on Organosilicons. However, so far, enzyme engineering has typically been a time-consuming, elaborate, expensive and inefficient process, usually requiring laborious, iterative trial-and-error optimization of engineered candidates
To accelerate the development of novel enzymes, our team harnessed the engineering strategy nature uses: Evolution.